Growth Metrics

Envoy Medical (COCH) Long-Term Deferred Tax (2022 - 2023)

Envoy Medical recorded quarterly Long-Term Deferred Tax of $50.2 million in Q4 2023, up 13.08% quarter-over-quarter from $44.4 million in Q4 2022, and up 13.08% year-over-year from $44.4 million in Q4 2022.

Envoy Medical's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $50.2 million for Q4 2023.

  • In Q4 2023, Long-Term Deferred Tax rose 13.08% year-over-year to $50.2 million; the TTM figure through Dec 2023 stood at $50.2 million (up 13.08% YoY), while the FY2023 annual figure was $50.2 million, up 13.08% from the prior year.
  • Long-Term Deferred Tax came in at $50.2 million for Q4 2023 at Envoy Medical, up from $44.4 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $50.2 million in Q4 2023 to a low of $44.4 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Envoy Medical 48.11 Mn 22.86 Mn -274,000.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 50.23 Mn
Dec 31, 2022 44.42 Mn